Alnylam suspends bleeding disorder trial dosing after patient death

Sept 7 (Reuters) - U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's death.

A patient suffering from hemophilia A enrolled in a mid-stage study of the experimental treatment, fitusiran, died after developing a blood clot, Alnylam said.

French drugmaker Sanofi has an alliance with Alnylam to co-develop fitusiran. (Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)